1. 1. Fowkes FG, Rudan D, Aboyans V, Denenberg JO, McDermott MM, Norman PE, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: A systemic review and analysis. Lancet 2013; 382: 1329–1340.
2. 2. Goodney PP, Beck AW, Nagle J, Welch HG, Zwolak RM. National trends in lower extremity bypass surgery, endovascular intervention and major amputations. J Vasc Surg 2009; 50: 54–60.
3. 3. Schillinger M, Saberi S, Dick P, Amighi J, Melkusch W, Schkager O, et al. Sustained benefit at 2 years of primary femoropopliteal stenting compared with balloon angioplasty with optimal stenting. Circulation 2007; 115: 2745–2749.
4. 4. Soga Y, Iida O, Hirono K, Yokoi H, Nanto S, Nobuyoshi M. Mid-term clinical outcome and predictors of vessel patency after femoropopliteal stenting with self-expandable nitinol stent. J Vasc Surg 2010; 52: 608–615.
5. 5. Dake DM, Ansel GM, Jaff MR, Ohki T, Saxon RR, Smouse HB, et al, Zilver PTX Investigators. Sustained safety and effectiveness of paclitaxel-eluting stents for femoropopliteal lesions: 2-year follow-up from the Zilver PTX randomized and single-arm clinical studies. J Am Coll Cardiol 2013; 61: 2417–2427.